ALKS (Alkermes) stock outlook for 2026. A deep qualitative look at the profitable CNS pharma's cash engine, VIVITROL, ARISTADA and LYBALVI, the INVEGA royalty runoff and patent cliff, the LUMRYZ franchise added through the Avadel deal, and the high-stakes alixorexton orexin pipeline.
Iyeon Pharmaceutical (KRX: 102460) 2026 stock outlook: its CT/MRI contrast media CDMO partnership with Bracco Imaging, the Chungju plant expansion, cephalosporin antibiotic API moat, raw-material-to-finished-dose integration, customer concentration risk, and how US investors can access this Korean small-cap.
Chong Kun Dang Bio (063160) 2026 stock outlook. A deep qualitative look at its fermentation-based active pharmaceutical ingredients, B2B probiotics raw-material franchise, CDMO growth optionality, plus the customer-concentration and Korean group-governance risks that keep the multiple in check.
Binex (053030) 2026 stock outlook. A deep qualitative look at the Korean biopharma CMO/CDMO model (antibody mammalian and microbial fermentation), small-batch multi-product flexibility versus Samsung Biologics scale, low-margin chemical drugs, and utilization and backlog volatility.
Huons (KOSDAQ 243070) stock outlook for 2026. A qualitative deep dive into its three-axis model of prescription pharma, contract manufacturing, and botulinum toxin and filler aesthetics, its niche generics in eye drops and local anesthetics, the Huons Global holding structure, toxin export momentum, valuation, and the key risks for a foreign investor.
A qualitative 2026 stock outlook for Celltrion Pharm (KOSDAQ 068760): its role distributing the Celltrion group's biosimilars in Korea, the Cheongju chemical-drug business, group governance and related-party risk, a rich valuation versus earnings, and dependence on the parent.
A qualitative 2026 outlook on Dong Kook Pharmaceutical (KOSPI 086450): the Madecassol and Insadol OTC brand moat, prescription-drug stability, Centellian24 cosmetics and health-functional-food growth, home-shopping channel dependence, drug-pricing risk, and the dividend case.
Biogen (BIIB) stock analysis for 2026. We evaluate Leqembi's actual prescription trajectory, the Spinraza revenue decline, Skyclarys rare disease growth, diranersen Phase 2 tau data, and whether the 55% bounce from $121 to $188 is justified.
Johnson & Johnson stock analysis 2026: post-Kenvue spin-off financials, talc litigation resolution path, MedTech vs Innovative Medicine segment dynamics, dividend history, and XLV comparison.
Merck (MRK) 2026 stock outlook: Keytruda patent cliff preparation ahead of 2028 expiry, subcutaneous formulation strategy, IRA drug pricing negotiation impact, next-generation oncology pipeline depth, dividend growth sustainability, and whether MRK fits in an income or growth portfolio.